(Q50753588)

English

Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.

scientific article published in November 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

1 reference

based on heuristic

inferred from title

author name string

C Schützinger

1

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

A Gaiger

2

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

R Thalhammer

3

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

M Vesely

4

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

R Fritsche-Polanz

5

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

I Schwarzinger

6

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

L Ohler

7

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

I Simonitsch-Klupp

8

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

F Reinhard

9

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

U Jäger

10

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

publication date

1 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

19

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

11

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

2005-2008

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403956

0 references

Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti‐CD52 monoclonal antibody alemtuzumab (Campath‐1H)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403956

21 January 2018

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403956

21 January 2018

Perspectives in the treatment of LGL leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403956

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of pure red cell aplasia with T large granular lymphocyte leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403956

7 January 2021

based on heuristic

inferred from DOI database lookup

Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403956

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403956

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403956

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403956

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/16193089

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50753588&oldid=1466080614"